- cafead   Jul 17, 2024 at 12:32: PM
via Roche has reported positive topline data from the ongoing multi-part Phase I clinical trial of CT-996, an oral GLP-1 receptor agonist, to treat type 2 diabetes (T2D) and obesity.
article source
article source